Biểu đồ giá cổ phiếu VNDA
VNDA Cổ tức
Vanda Pharmaceuticals Inc
$7.44
0.67%
$0.05
Khi đóng cửa: May 06, 16:00:00 GMT-4
$7.16
-3.76%
$-0.28
Phiên sau giờ: May 06, 20:00:00 GMT-4
Quay lại
Vanda Pharmaceuticals Inc (VNDA) Cổ tức
Thống kê chính
Giá đóng cửa trước
$7.39
Giá mở cửa
$7.51
Phạm vi ngày
$7.16 - $7.73
Phạm vi 52 tuần
$3.8 - $9.94
Khối lượng
1.6M
Khối lượng trung bình
2.4M
Tỷ suất cổ tức
--
EPS (TTM)
-3.74
Vốn hóa thị trường
$423.2M
VNDA là gì?
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 533 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
